We at Alpha-1 Awareness have some wonderful news that we would like to share with you. Internal Promotion Glyn Cockaday joined our charity Board 3 years ago as our Facebook Admin.  Glyn not only excelled at this role, but started to help with many other internal projects and often tookContinue Reading

SHAPLEIGH (WGME) — A woman in need of a double lung transplant says she’s running out of time and blames a change in policy. Valarie Hale isn’t living life the way she’d like to. “I have an inherited disease, auto-immune disease, called Alpha-1 Antitrypsin Deficiency,” said Hale. It affects herContinue Reading

SAN DIEGO, September 4, 2019 /PRNewswire/ — Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today the enrollment of the first patient in a Phase 1 clinical trial of INBRX-101 (NCT03815396). INBRX-101 is an Fc-fusion protein-based therapeutic candidate comprised ofContinue Reading

Michigan becomes the first state to ban flavored e-cigarettes for minors starting today. Governor Gretchen Whitmer has been making a push to get nicotine out of teens hands. She has publicly stated several times the importance of making sure non-traditional nicotine products are not sold to young people. Back in June, sheContinue Reading

REHOVOT, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today the extension of its strategic supply agreement with Takeda for GLASSIA® [Alpha1-Proteinase Inhibitor (Human)].  Kamada will now continue to produce GLASSIA for Takeda through 2021.  Based on the extended agreement, KamadaContinue Reading

Ronald G. Crystal, MD, is chair of the department of genetic medicine at Weill Cornell Medical College in New York, where he has worked for 26 years. He is one of the pioneers of gene therapy. After training with W. French Anderson, he led some of the first in vivoContinue Reading